http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005511689-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-10 |
| filingDate | 2002-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005511689-A |
| titleOfInvention | Novel specificity inhibitor compound of phospholipase A2 secreted from group II human non-pancreas |
| abstract | The compounds according to the present invention are completely inactive against group I pancreatic PLA 2 and have selective inhibitory activity against group II PLA 2 and also have in vivo activity higher than that of indomethacin. In addition, the compound according to the present invention has an excellent bioavailability when administered by the oral route. 【Task】 The present invention relates to a compound of formula I below and a pharmaceutical composition comprising the compound of formula I. [Chemical I] In the formula, D, Y, A, B, p, q, W and R are as defined in the detailed description of the invention. |
| priorityDate | 2001-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 192.